Actinomycin D for fibrosis management in ophthalmic implant surgery
Implants that feature a drug delivery system loaded with antifibrotic active drugs provide a promising approach to address postoperative complications caused by fibrosis. This study is intended to clarify whether Actinomycin D has an impact specifically on components of the extracellular matrix (ECM...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2019-09-01
|
| Series: | Current Directions in Biomedical Engineering |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/cdbme-2019-0121 |
| _version_ | 1811194202928709632 |
|---|---|
| author | Brietzke Andreas Eickner Thomas Grabow Niels Reske Thomas Matschegewski Claudia Guthoff Rudolf Stahnke Thomas |
| author_facet | Brietzke Andreas Eickner Thomas Grabow Niels Reske Thomas Matschegewski Claudia Guthoff Rudolf Stahnke Thomas |
| author_sort | Brietzke Andreas |
| collection | DOAJ |
| description | Implants that feature a drug delivery system loaded with antifibrotic active drugs provide a promising approach to address postoperative complications caused by fibrosis. This study is intended to clarify whether Actinomycin D has an impact specifically on components of the extracellular matrix (ECM) and its formation in human primary fibroblasts of the Tenon capsule (hTF). Furthermore, the suitability of this agent in poly(N-vinylpyrrolidone)- poly(methylmethacrylate)(PVP-co-PMMA) as a drug delivery model is evaluated in drug incorporation and release studies. RT-qPCR revealed a significant downregulation of the fibrotic marker genes ACTA2, COL1A1 and FN1 in cells stimulated with TGF- β1 and additionally treated with Actinomycin D. However, these findings could only be confirmed on α- SMA protein level. collagen I and Fibronectin synthesis stayed unaffected. The diffusion based incorporation of Actinomycin D into the polymer model proved to be very effective. The release of the agent was retarded with a slightly prolonged kinetic. These findings make Actinomycin D a promising antifibrotic agent in ophthalmic implant surgery. |
| first_indexed | 2024-04-12T00:22:00Z |
| format | Article |
| id | doaj.art-29101e358640468e8a38fed584264c4f |
| institution | Directory Open Access Journal |
| issn | 2364-5504 |
| language | English |
| last_indexed | 2024-04-12T00:22:00Z |
| publishDate | 2019-09-01 |
| publisher | De Gruyter |
| record_format | Article |
| series | Current Directions in Biomedical Engineering |
| spelling | doaj.art-29101e358640468e8a38fed584264c4f2022-12-22T03:55:41ZengDe GruyterCurrent Directions in Biomedical Engineering2364-55042019-09-015148148310.1515/cdbme-2019-0121cdbme-2019-0121Actinomycin D for fibrosis management in ophthalmic implant surgeryBrietzke Andreas0Eickner Thomas1Grabow Niels2Reske Thomas3Matschegewski Claudia4Guthoff Rudolf5Stahnke Thomas6Institute for Biomedical Engineering, Rostock University Medical Center, Friedrich-Barnewitz-Straße 4, D-18119Rostock, GermanyInstitute for Biomedical Engineering, Rostock University Medical Center, D-18119Rostock, GermanyInstitute for Biomedical Engineering, Rostock University Medical Center, D-18119Rostock, GermanyInstitute for ImplantTechnology and Biomaterials e.V., Friedrich-Barnewitz- Straße 4, D-18119Rostock, GermanyInstitute for ImplantTechnology and Biomaterials e.V., Friedrich-Barnewitz- Straße 4, D-18119Rostock, GermanyDepartment of Ophthalmology, Rostock University Medical Center, Doberaner Straße 140, D-18057Rostock, GermanyDepartment of Ophthalmology, Rostock University Medical Center, Doberaner Straße 140, D-18057Rostock, GermanyImplants that feature a drug delivery system loaded with antifibrotic active drugs provide a promising approach to address postoperative complications caused by fibrosis. This study is intended to clarify whether Actinomycin D has an impact specifically on components of the extracellular matrix (ECM) and its formation in human primary fibroblasts of the Tenon capsule (hTF). Furthermore, the suitability of this agent in poly(N-vinylpyrrolidone)- poly(methylmethacrylate)(PVP-co-PMMA) as a drug delivery model is evaluated in drug incorporation and release studies. RT-qPCR revealed a significant downregulation of the fibrotic marker genes ACTA2, COL1A1 and FN1 in cells stimulated with TGF- β1 and additionally treated with Actinomycin D. However, these findings could only be confirmed on α- SMA protein level. collagen I and Fibronectin synthesis stayed unaffected. The diffusion based incorporation of Actinomycin D into the polymer model proved to be very effective. The release of the agent was retarded with a slightly prolonged kinetic. These findings make Actinomycin D a promising antifibrotic agent in ophthalmic implant surgery.https://doi.org/10.1515/cdbme-2019-0121fibrosisophthalmic implantdrug deliveryactinomycin d |
| spellingShingle | Brietzke Andreas Eickner Thomas Grabow Niels Reske Thomas Matschegewski Claudia Guthoff Rudolf Stahnke Thomas Actinomycin D for fibrosis management in ophthalmic implant surgery Current Directions in Biomedical Engineering fibrosis ophthalmic implant drug delivery actinomycin d |
| title | Actinomycin D for fibrosis management in ophthalmic implant surgery |
| title_full | Actinomycin D for fibrosis management in ophthalmic implant surgery |
| title_fullStr | Actinomycin D for fibrosis management in ophthalmic implant surgery |
| title_full_unstemmed | Actinomycin D for fibrosis management in ophthalmic implant surgery |
| title_short | Actinomycin D for fibrosis management in ophthalmic implant surgery |
| title_sort | actinomycin d for fibrosis management in ophthalmic implant surgery |
| topic | fibrosis ophthalmic implant drug delivery actinomycin d |
| url | https://doi.org/10.1515/cdbme-2019-0121 |
| work_keys_str_mv | AT brietzkeandreas actinomycindforfibrosismanagementinophthalmicimplantsurgery AT eicknerthomas actinomycindforfibrosismanagementinophthalmicimplantsurgery AT grabowniels actinomycindforfibrosismanagementinophthalmicimplantsurgery AT reskethomas actinomycindforfibrosismanagementinophthalmicimplantsurgery AT matschegewskiclaudia actinomycindforfibrosismanagementinophthalmicimplantsurgery AT guthoffrudolf actinomycindforfibrosismanagementinophthalmicimplantsurgery AT stahnkethomas actinomycindforfibrosismanagementinophthalmicimplantsurgery |